Linked Life Data

1444498

Source:http://linkedlifedata.com/resource/pubmed/id/1444498

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13
pubmed:dateCreated
1992-12-16
pubmed:abstractText
Hydroxycarbamide (the brand name: Hydrea) was found effective to chronic myelogenous leukemia (CML) in Japan. In the preclinical study, this compound was active against mouse leukemia L 1210 and inhibited DNA synthesis. Clinically, Hydrea was given orally at the daily dose of 500-2,000 mg, dividing 1-3 times. For the maintenance therapy after remission induction, daily dose of 500-1,000 mg was given, dividing 1-2 times. As for the side effects, myelosuppression, disturbance of the gastro-intestinal tract and temporal liver and renal dysfunctions were observed. The response rate in the remission-induction therapy was as high as 92.1%.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2275-80
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
[Hydrea, an effective drug for chronic myelogenous leukemia].
pubmed:affiliation
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo.
pubmed:publicationType
Journal Article, English Abstract